Pancreatic cancer is the fifth commonest cause of cancer death in the UK. While overall survival for most cancers has improved over the past 30 years, this has not been replicated in patients with pancreatic ductal adenocarcinoma (PDAC), of whom only 2-3% survive five years from diagnosis.
Finding better ways to detect and treat pancreatic cancer
Link to Precision-Panc website: www.precisionpanc.org
Link to Glasgow Precision Oncology Laboratory: www.gpol.org
Our goal is to develop strategies for the early detection of pre-invasive disease and to evaluate potential anti-invasive therapies in advanced disease in order to improve survival rates.
We aim to:
- Determine whether we can use genetics to stratify patient outcomes.
- Identify previously unreported genetic lesions that influence pancreatic cancer.
- Investigate the role of microRNAs in pancreatic biology, including their prognostic and therapeutic value.
- Study effects of inflammation on pancreatic cancer, and explore therapeutic opportunities that target inflammation, including immunotherapy signalling pathways.
- Study the pancreatic cancer stromal interaction, and explore therapeutic opportunities that target the stroma.
The following funding agencies sponsor our work:
Some recent publications:
Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 2012; 18: 534-45 Dozynkiewicz MA, Jamieson NB, Macpherson I, Grindlay J, van den Berghe PV, von Thun A, Morton JP, Gourley C, Timpson P, Nixon C, McKay CJ, Carter R, Strachan D, Anderson K, Sansom OJ, Caswell PT, Norman JC. Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression. Dev Cell 2012; 22: 131-45